TY - JOUR
T1 - Diabetes and long-term outcomes of ischaemic stroke
T2 - Findings from get with the guidelines-stroke
AU - Echouffo-Tcheugui, Justin B.
AU - Xu, Haolin
AU - Matsouaka, Roland A.
AU - Xian, Ying
AU - Schwamm, Lee H.
AU - Smith, Eric E.
AU - Bhatt, Deepak L.
AU - Hernandez, Adrian F.
AU - Heidenreich, Paul A.
AU - Fonarow, Gregg C.
N1 - Funding Information:
The study cohort was formed from the Get With The Guidelines (GWTG)-Stroke, a national prospective stroke registry and quality improvement program sponsored by the American Heart Association (AHA)/American Stroke Association (ASA). Details of the design and conduct of the GWTG-Stroke registry have been previously described.7 In GWTG-Stroke, participating hospitals use an internet-based patient management tool (IQVIA, Inc, Durham NC) to add data to a central database on consecutive acute IS patients. The methods for data extraction have been previously described,8 as well as the validity and reliability of data collection.9 As the primary objective of data collection is quality improvement, each participating hospital received either human research approval to enrol cases without individual patient consent under the common rule or a waiver of authorization and exemption from subsequent review by their Institutional Review Board. The Duke Clinical Research Institute serves as the data analysis centre.
Funding Information:
This work was supported by the Get with the Guidelines-Stroke (GWTG-Stroke) program, which is provided by the American Heart Association (AHA)/American Stroke Association. The GWTG-Stroke program is supported, in part, by a charitable contribution from Janssen Pharmaceutical Companies of Johnson & Johnson. GWTG-Stroke has been funded in the past through support from Boeringher-Ingelheim, Merck, Bristol-Myers Squib/Sanofi Pharmaceutical Partnership, and the AHA Pharmaceutical Roundtable (PRT). J.B.E. was awarded an American Heart Association/American Stroke Association (AHA/ASA) - Young Investigator Database Research Seed Grant in 2015 to conduct this study. J.B.E. is supported by the National Heart, Lung, and Blood Institute (NHLBI) grant T32 HL125232.
Publisher Copyright:
© The Author(s)2018 All rights reserved.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Aims There is a paucity of data on the influence of diabetes on long-term outcomes after ischaemic stroke (IS). We assessed whether outcomes after IS differ between patients with and without diabetes. Methods Patients aged >_65 years (n = 409 060) in Get With The Guidelines-Stroke (nationwide registry of stroke patients and results from 1690 sites in the USA) were followed for 3 years post-discharge. The outcomes of interest were mortality, cardiovascular and non-cardiovascular hospitalizations, heart failure (HF), and recurrence of IS/transient ischaemic attack (TIA). Patients with diabetes (29.6%) were younger and had more comorbidities. At 3 years post-discharge after IS, diabetes was associated with higher risks of adverse outcomes: all-cause mortality [cumulative incidence 46.0% vs. 44.2%, absolute difference (AD) 1.8%; adjusted hazard ratio (aHR) 1.24, 95% confidence interval 1.23–1.25], all-cause readmission (71.3% vs. 63.7%, AD 7.6%; aHR 1.22, 1.21–1.23), composite of mortality and all-cause readmission (84.1% vs. 79.3%, AD 4.8%; aHR 1.21, 1.20–1.22), composite of mortality and cardiovascular readmission (69.5% vs. 64.3%, AD 5.2%; aHR 1.19, 1.18–1.20), IS/TIA readmission (15.9% vs. 13.3%, AD 2.6%; aHR 1.18, 1.16–1.20), HF readmission (10.3% vs. 6.4%, AD 3.9%; aHR 1.60, 1.56–1.64), non-cardiovascular readmission (58.3% vs. 50.3%, AD 8.0%; aHR 1.28, 1.26–1.29), and non-IS/TIA readmission (67.6% vs. 59.7%, AD 7.9%; aHR 1.23, 1.22–1.25). Accounting for the initial severity of stroke using the National Institute of Health Stroke Scale as well as using propensity score matching method as a sensitivity analysis, did not modify the results.Conclusion Among older IS patients diabetes was associated with increased risks of death, cardiovascular and non-cardiovascular hospitalizations, HF, and IS/TIA recurrence.
AB - Aims There is a paucity of data on the influence of diabetes on long-term outcomes after ischaemic stroke (IS). We assessed whether outcomes after IS differ between patients with and without diabetes. Methods Patients aged >_65 years (n = 409 060) in Get With The Guidelines-Stroke (nationwide registry of stroke patients and results from 1690 sites in the USA) were followed for 3 years post-discharge. The outcomes of interest were mortality, cardiovascular and non-cardiovascular hospitalizations, heart failure (HF), and recurrence of IS/transient ischaemic attack (TIA). Patients with diabetes (29.6%) were younger and had more comorbidities. At 3 years post-discharge after IS, diabetes was associated with higher risks of adverse outcomes: all-cause mortality [cumulative incidence 46.0% vs. 44.2%, absolute difference (AD) 1.8%; adjusted hazard ratio (aHR) 1.24, 95% confidence interval 1.23–1.25], all-cause readmission (71.3% vs. 63.7%, AD 7.6%; aHR 1.22, 1.21–1.23), composite of mortality and all-cause readmission (84.1% vs. 79.3%, AD 4.8%; aHR 1.21, 1.20–1.22), composite of mortality and cardiovascular readmission (69.5% vs. 64.3%, AD 5.2%; aHR 1.19, 1.18–1.20), IS/TIA readmission (15.9% vs. 13.3%, AD 2.6%; aHR 1.18, 1.16–1.20), HF readmission (10.3% vs. 6.4%, AD 3.9%; aHR 1.60, 1.56–1.64), non-cardiovascular readmission (58.3% vs. 50.3%, AD 8.0%; aHR 1.28, 1.26–1.29), and non-IS/TIA readmission (67.6% vs. 59.7%, AD 7.9%; aHR 1.23, 1.22–1.25). Accounting for the initial severity of stroke using the National Institute of Health Stroke Scale as well as using propensity score matching method as a sensitivity analysis, did not modify the results.Conclusion Among older IS patients diabetes was associated with increased risks of death, cardiovascular and non-cardiovascular hospitalizations, HF, and IS/TIA recurrence.
KW - Diabetes
KW - Glycated haemoglobin
KW - Ischaemic stroke
KW - Stroke
KW - Transient ischaemic attack
UR - http://www.scopus.com/inward/record.url?scp=85050592744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050592744&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehy036
DO - 10.1093/eurheartj/ehy036
M3 - Article
C2 - 29438515
AN - SCOPUS:85050592744
SN - 0195-668X
VL - 39
SP - 2376
EP - 2386
JO - European Heart Journal
JF - European Heart Journal
IS - 25
ER -